(firstQuint)Ampligen in Chronic Fatigue Syndrome.

 An Open-Label Study of Poly I: Poly C12U (Ampligen(R)) in Patients with Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME).

 The FDA approved the study for cost recovery.

 Patients enrolled in the study are responsible for costs related to the therapy, e.

g.

, drug cost, infusion cost, cost of supplies, diagnostic and other laboratory testing.

.

 Ampligen in Chronic Fatigue Syndrome@highlight

This is an open label study of Ampligen in patients with chronic fatigue syndrome.

